Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2021
Message from the CEO
IBT is conducting a phase III-study ( The Connection Study ) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing
Lactobacillus reuteri as active substance. The active substance is a human bacterial strain found naturally in breast milk. The objective of the study is to show that the active substance can prevent necrotizing enterocolitis (NEC) and improve sustained feeding tolerance.
The medical need of a well-functioning digestion system is very high in premature infants and it is our expectation that IBT s pharmaceutical candidate IBP-9414 may improve gut motility in nutritional uptake, and simultaneously also reduce the risk for several complications such as NEC.
Even those familiar with the legacy of Sesame Street will discover new and fascinating things about the show’s history in the new documentary Street Gang
The Ministry of Social Development has urged the people to contact 110o incase in case they come across following incidents. Children exposed to violence, abuse or insult. Children not enrolled to education Children who did not receive the immunization that is prescribed for them. Children begging alone or with adults.